Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease

Maher, Maha M.; Nassar, Mahmoud I.
November 2009
Digestive Diseases & Sciences;Nov2009, Vol. 54 Issue 11, p2456
Academic Journal
journal article
The role of cytomegalovirus (CMV) infection in patients with inflammatory bowel disease (IBD) is controversial. Although CMV has been specifically associated with refractory disease, the strength and nature of this association have been a subject of debate. The aim of this study was to evaluate the prevalence and outcome of acute cytomegalovirus infection in patients with severe refractory and complicated inflammatory bowel disease. Seventy-two patients with active IBD (both ulcerative colitis [UC] and Crohn’s diseases [CD]) were included in this study. Thorough history taking and physical examination of all patients was made with special emphasis on symptoms and signs of CMV disease. Colonoscopic assessment was made for the extent and activity of IBD and collection of specimen. Prevalence of CMV infection was estimated by serology; anti-CMV IgM and IgG antibodies, and pathologic studies of colonic biopsies used conventional haematoxylin and eosin (H & E) and immunohistochemistry (IHC) with monoclonal antibodies. Complete blood count and liver function tests were done for all patients. Among 72 patients with active inflammatory bowel disease, 23 (31.9%) were resistant to intravenous steroids. CMV was detected in eight (six with UC and two with CD) of the 23 (34.8%) steroid-resistant patients and in only one (3.2%) patient in the remaining 31 patients under steroid treatment and was not detected in 18 IBD patients not using steroids. Among nine CMV-positive IBD patients, six (66.6%) were female and six had fever; cervical lymphadenopathy was found in five patients and splenomegaly in two, compared to no patients in the CMV-negative group ( P = 0.01 and 0.03, respectively). Leucopenia and thrombocytopenia were predominantly seen in the CMV-positive versus CMV-negative patients (2.1±0.3 vs. 5.9±3.4 and 98±34 vs. 165±101, respectively). Pancolitis was found in five of nine CMV-positive IBD patients whereas in only two patients out of 63 in the CMV-negative group ( P = 0.005). Acute CMV infection in patients with IBD is not rare and is often underestimated. CMV infection in patients with refractory or complicated IBD should be ruled out before aggressive immunosuppressive therapy. High clinical index of suspicion for the association of CMV infection with IBD should be directed towards female IBD patients presenting with fever, lymphadenopathy, splenomegaly, leucopenia, and mild hepatitis. CMV IHC is significantly more sensitive than routine H & E stain and should be considered as part of the routine evaluation of IBD patients with severe exacerbation or steroid-refractory disease before proceeding with other medical or surgical therapy that may not be necessary once the CMV is treated.


Related Articles

  • Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Kang, Yun-Seong; Moon, Hyoung; Lee, Seung; Lim, Yun; Kang, Hyoun // Digestive Diseases & Sciences;Apr2015, Vol. 60 Issue 4, p951 

    Background: CT-P13 is the first biosimilar monoclonal antibody to infliximab. However, the antibody was tested only in rheumatoid arthritis and ankylosing spondylitis, which demonstrated equivalence to the originator in efficacy, safety, and pharmacokinetic profile. Extrapolation of its efficacy...

  • Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy. Miranda-Bautista, José; Gracia-Fernández, Celia; López-Ibáñez, María; Barrientos, María; Gallo-Moltó, Alejandra; González-Arias, Marina; González-Gil, Casilda; Díaz-Redondo, Alicia; Marín-Jiménez, Ignacio; Menchén, Luis // Digestive Diseases & Sciences;Jul2015, Vol. 60 Issue 7, p2130 

    Background: Previous studies analyzing lipid profile in small cohorts of patients with rheumatic and inflammatory bowel diseases (IBD) treated with TNFα blockers showed conflicting results. We aim to evaluate the effect of anti-TNFα monoclonal antibodies, infliximab and adalimumab, on...

  • Azathioprine.  // Reactions Weekly;6/7/2008, Issue 1205, p8 

    The article describes the case of a girl with Crohn's disease who developed cytomegalovirus (CMV) infection and pancytopenia, followed by paradoxical elevation of thiopurine-S-methyltransferase (TPMT) activity during treatment with azathioprine. The girl has undergone left hemicolectomy in the...

  • Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Sabatier, J; Uro-Coste, E; Pommepuy, I; Labrousse, F; Allart, S; Trímoulet, M; Delisle, M B; Brousset, P // British Journal of Cancer;2/28/2005, Vol. 92 Issue 4, p747 

    Human cytomegalovirus (HCMV) genome and related proteins have been reported in a great proportion of malignant gliomas. However, these results are unexpected since HCMV is not known as an oncogenic virus. By immunohistochemistry (with an anti-IE1 monoclonal antibody) and in situ hybridisation...

  • Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Cullen, Garret; Bader, Caroline; Korzenik, Joshua R.; Sands, Bruce E. // Gut;Mar2012, Vol. 61 Issue 3, p385 

    Background Influenza vaccination is recommended for patients with inflammatory bowel disease (IBD). The 2009 H1N1 influenza vaccine produced seroprotection rates of >85% in the general population but there are no data on the immunogenicity of the vaccine in patients with IBD. Methods An...

  • Evaluation of Early Atherosclerosis in Patients with Inflammatory Bowel Disease. Kayahan, Hasan; Sari, Ismail; Cullu, Nesat; Yuksel, Fahize; Demir, Serdal; Akarsu, Mesut; Goktay, Yigit; Unsal, Belkis; Akpinar, Hale // Digestive Diseases & Sciences;Aug2012, Vol. 57 Issue 8, p2137 

    Background: Data regarding early atherosclerosis and inflammatory bowel disease are limited and conflicting results are present. Aims: The purpose of this study was to evaluate serological and sonographical evidence of subclinical vascular involvement in patients with inflammatory bowel disease....

  • Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease. Dong, Xiuli; Ye, Xiaohua; Chen, Xiangrong; Chen, Tanzhou; Xie, Saili; Li, Qinfan; Lin, Xiaoxiao; Huang, Zhiming // Digestive Diseases & Sciences;Apr2014, Vol. 59 Issue 4, p769 

    Background: Fibrinogen-like protein 2 (FGL2), a new member of the fibrinogen-like family, has recently been identified as a novel immunosuppressive molecule. Aim: The purpose of this work was to investigate intestinal and peripheral expression of FGL2 in patients with inflammatory bowel disease...

  • Immunosuppressants.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p52 

    The article describes the case of a 35-year-old woman with systemic lupus erythematosus and lupus nephritis who developed a cavitary pulmonary lesion as a manifestation of cytomegalovirus pneumonitis while taking immunosuppressive therapy. After admission, she was given methylprednisolone, oral...

  • Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease.  // Inflammatory Bowel Disease Monitor;2011, Vol. 11 Issue 3, p126 

    The article presents a study on the role of microRNAs (miRNAs) in inactive colonic mucosa of patients with inflammatory bowel disease (IBD).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics